Cellectar Biosciences, Inc. (CLRB) — Financial statements
Income statement, balance sheet, and cash flow for Cellectar Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 11↓56.0% | 26↓4.1% | 27↑41.9% | 19↑9.3% | 18 | |
| General & Administrative Expenses | 11↓55.2% | 26↑119.3% | 12↑21.9% | 10↑46.6% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓55.2% | 26↑119.3% | 12↑21.9% | 10↑46.6% | 7 | |
| Other Expenses | -0.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 23↓56.0% | 52↑32.9% | 39↑35.2% | 29↑19.4% | 24 | |
| Total Costs & Expenses | 23↓55.6% | 52↑32.9% | 39↑35.2% | 29↑19.4% | 24 | |
| Operating Results | ||||||
| Operating Income | -23↑55.6% | -52↓32.9% | -39↓35.2% | -29↓19.4% | -24 | |
| Depreciation & Amortization | 0.21↓26.8% | 0.29↑51.6% | 0.19↑29.6% | 0.15↓1.0% | 0.15 | |
| EBITDA | -23↑55.8% | -51↓32.8% | -39↓35.2% | -29↓19.5% | -24 | |
| EBIT | -23↑55.6% | -52↓32.9% | -39↓35.2% | -29↓19.4% | -24 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.44↓64.1% | 1↑212.8% | 0.39↑153.8% | 0.15↑6577.7% | 0.00 | |
| Interest Income | 0.44↓64.1% | 1↑212.8% | 0.39↑153.8% | 0.15↑6577.7% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 1↓83.6% | 7↑287.7% | -4↓27.3% | -3↓34175.4% | 0.01 | |
| Income Before Tax | -22↑51.0% | -45↓3.9% | -43↓34.5% | -32↓32.0% | -24 | |
| Income Tax Expense | 0.00↓100.0% | 0.07↑210.0% | -0.06↑0.0% | -0.06 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -22↑51.1% | -45↓4.2% | -43↓34.5% | -32↓31.8% | -24 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -22↑51.1% | -45↓4.2% | -43↓34.5% | -32↓31.8% | -24 | |
| Bottom-Line Net Income | -22↑51.1% | -45↓4.2% | -43↓34.5% | -32↓31.8% | -24 | |
| EPS (Basic) | -8.35↑77.1% | -36.52↑65.2% | -104.99↑22.3% | -135.18↓3.7% | -130.35 | |
| EPS (Diluted) | -8.35↑80.1% | -41.89↑60.1% | -104.99↑22.3% | -135.18↓3.7% | -130.35 | |
| Weighted Average Shares | 3↑113.7% | 1↑199.7% | 0.41↑73.2% | 0.24↑27.1% | 0.19 | |
| Weighted Average Diluted Shares | 3↑110.7% | 1↑203.9% | 0.41↑73.2% | 0.24↑27.1% | 0.19 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.